PE20121437A1 - Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetes - Google Patents

Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetes

Info

Publication number
PE20121437A1
PE20121437A1 PE2012000492A PE2012000492A PE20121437A1 PE 20121437 A1 PE20121437 A1 PE 20121437A1 PE 2012000492 A PE2012000492 A PE 2012000492A PE 2012000492 A PE2012000492 A PE 2012000492A PE 20121437 A1 PE20121437 A1 PE 20121437A1
Authority
PE
Peru
Prior art keywords
alkyl
diabetes
treatment
phenyl
pharmaceutical use
Prior art date
Application number
PE2012000492A
Other languages
English (en)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121437(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20121437A1 publication Critical patent/PE20121437A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE ESPIROPIPERIDINA DE FORMULA (I) DONDE: R1 ES H, F Y CLORO; R2 ES H, ALQUILO C1-3, CF3, OCH3, F Y CLORO; R3 ES H Y ALQUILO C1-3; R4 Y R4a SON INDEPENDIENTEMENTE H, OCH3, ALQUILO C1-3, CF3 Y FLUOR; R5 ES H O C?CCH3; X ES CH(R3)CH2-, -C(R3)=CH-, -N(R7)CH2- Y -C(O)CH2-; R7 ES H, ALQUILO C1-3 Y FENILO; SON COMPUESTOS PREFERIDOS: ACIDO (3S)-3-(4-{[4-(1'H-ESPIRO[INDEN-1,4'-PIPERIDIN]-1'-ILMETIL)BENCIL]OXI}FENIL)HEX-4-INOICO; ACIDO (3S)-3-[4-({4-[(1-METIL-1,2,-DIHIDRO-1'H-ESPIRO[INDOL-3,4'-PIPERIDIN]-1'-IL)METIL]BENCIL}OXI)FENIL]HEX-4-INOICO; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES MODULADOR DEL RECEPTOR 40 ACOPLADO A LA PROTEINA G (RPG-40), SIENDO UTIL EN EL TRATAMIENTO DE LA DIABETES
PE2012000492A 2009-10-15 2010-10-11 Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetes PE20121437A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US30333410P 2010-02-11 2010-02-11

Publications (1)

Publication Number Publication Date
PE20121437A1 true PE20121437A1 (es) 2012-10-26

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000492A PE20121437A1 (es) 2009-10-15 2010-10-11 Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetes

Country Status (24)

Country Link
US (1) US8383642B2 (es)
EP (1) EP2488500A1 (es)
JP (1) JP2013508279A (es)
KR (1) KR20120051777A (es)
CN (1) CN102574807A (es)
AR (1) AR078522A1 (es)
AU (1) AU2010307094A1 (es)
BR (1) BR112012008889A2 (es)
CA (1) CA2777775A1 (es)
CL (1) CL2012000921A1 (es)
CO (1) CO6531458A2 (es)
CR (1) CR20120177A (es)
DO (1) DOP2012000105A (es)
EA (1) EA201270560A1 (es)
EC (1) ECSP12011799A (es)
IL (1) IL218344A0 (es)
MA (1) MA33662B1 (es)
MX (1) MX2012004420A (es)
NZ (1) NZ598972A (es)
PE (1) PE20121437A1 (es)
TN (1) TN2012000152A1 (es)
TW (1) TW201124415A (es)
WO (1) WO2011046851A1 (es)
ZA (1) ZA201202560B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2411395T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne furopirymidynodionu jako modulatory TRPA1
AU2010227245B2 (en) 2009-03-23 2015-09-10 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
AR078948A1 (es) * 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
EA201290574A1 (ru) 2009-12-25 2012-12-28 Мотида Фармасьютикал Ко., Лтд. Новое производное 3-гидрокси-5-арилизотиазола
CA2813639A1 (en) 2010-10-08 2012-04-12 Mochida Pharmaceutical Co. Ltd. Cyclic amide derivative
BR112013022712A2 (pt) 2011-03-11 2016-08-09 Intercontinental Great Brands Llc sistema e método de formar produto de confeitaria de múltiplas camadas
NZ617409A (en) 2011-04-27 2015-08-28 Mochida Pharm Co Ltd Novel 3-hydroxyisothiazole 1-oxide derivative
CA2834465A1 (en) 2011-04-28 2012-11-01 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
AR087451A1 (es) 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
SI2920165T1 (sl) 2012-11-16 2017-02-28 Bristol-Myers Squibb Company Modulatorji dihidropirazola GPR40
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
JP6352415B2 (ja) 2013-11-14 2018-07-04 カディラ・ヘルスケア・リミテッド 新規なヘテロ環化合物
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
ES2869910T3 (es) * 2014-10-17 2021-10-26 Hyundai Pharm Co Ltd Preparación compuesta, que contiene un nuevo derivado de ácido 3-(4-(benciloxi)fenil)hex-4-inoico y otro principio activo, para prevenir o tratar enfermedades metabólicas
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
BR112020013694A2 (pt) 2018-01-08 2020-12-01 Celon Pharma S.A. derivados de ácido 3-fenil-4-hexinôico como agonistas gpr40
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7105359B2 (ja) 2018-07-13 2022-07-22 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス．エイ． スピロインデンおよびスピロインダン化合物類
WO2004089307A2 (en) * 2003-04-04 2004-10-21 Merck & Co. Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
MXPA06005038A (es) 2003-11-04 2007-12-12 Elixir Pharmaceuticals Inc Compuestos terapeuticos y usos de los mismos.
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
AU2007292816B2 (en) 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2684861A3 (en) 2007-10-26 2014-05-07 Japan Tobacco Inc. Spiro compounds and pharmaceutical use thereof
JP2011504499A (ja) 2007-11-21 2011-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリプターゼ阻害剤として使用するためのスピロピペリジン
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
ECSP12011799A (es) 2012-07-31
TN2012000152A1 (en) 2013-12-12
AR078522A1 (es) 2011-11-16
EP2488500A1 (en) 2012-08-22
US8383642B2 (en) 2013-02-26
US20110092531A1 (en) 2011-04-21
IL218344A0 (en) 2012-04-30
JP2013508279A (ja) 2013-03-07
ZA201202560B (en) 2013-09-25
WO2011046851A1 (en) 2011-04-21
DOP2012000105A (es) 2013-01-31
BR112012008889A2 (pt) 2019-09-24
CL2012000921A1 (es) 2012-09-14
EA201270560A1 (ru) 2012-09-28
CN102574807A (zh) 2012-07-11
MA33662B1 (fr) 2012-10-01
CR20120177A (es) 2012-06-06
NZ598972A (en) 2013-06-28
KR20120051777A (ko) 2012-05-22
TW201124415A (en) 2011-07-16
CA2777775A1 (en) 2011-04-21
AU2010307094A1 (en) 2012-04-19
CO6531458A2 (es) 2012-09-28
MX2012004420A (es) 2012-05-08

Similar Documents

Publication Publication Date Title
PE20121437A1 (es) Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetes
PE20121474A1 (es) Nuevos compuestos de espiropiperidina
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
PE20121518A1 (es) Bloqueantes de los canales de sodio dependientes de voltaje
PE20070355A1 (es) Antagonistas de cgrp seleccionados y procedimientos para su preparacion
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
PE20090815A1 (es) Compuesto de amida
PE20120261A1 (es) Piperidina espiro pirrolidinona y piperidinonas sustitudos como moduladores de los receptores h3
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
PE20091816A1 (es) Inhibidores de bace
AR072900A1 (es) Agentes terapeuticos derivados de pirazolo[3,4-d]pirimidina
PE20080706A1 (es) Arilmidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
PE20121031A1 (es) Nuevos conjugados, su preparacion y su aplicacion terapeutica
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
PE20110329A1 (es) Agonistas del receptor acoplado a la proteina g piperidinilo
NZ613234A (en) Compositions and methods for modulating fxr
PE20061049A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida como antagonistas del receptor de vanilloides tipo 1 (vr1)
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
RU2008136756A (ru) Гетеробициклические противовирусные соединения
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20090949A1 (es) Compuesto heterociclico y composicion farmaceutica del mismo

Legal Events

Date Code Title Description
FD Application declared void or lapsed